←Back to Expert Scholars
Translational Medicine / 转化医学Rare Adult Tumors, Precision Oncology
Vivek Subbiah
MD
🏢Sarah Cannon Research Institute🌐USA
Chief of Early Phase Drug Development
75
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Vivek Subbiah has led first-in-human and registrational studies of selpercatinib, pralsetinib, and larotrectinib in rare RET- and NTRK-driven cancers across histologies. His tissue-agnostic development work has enabled multiple FDA approvals. He champions access and trials for ultra-rare cancers.
Share:
🧪Research Fields 研究领域
rare tumor precision
RET inhibitors
NTRK fusion cancers
basket trials rare
tissue-agnostic drugs
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Vivek Subbiah 的研究动态
Follow Vivek Subbiah's research updates
留下邮箱，当我们发布与 Vivek Subbiah（Sarah Cannon Research Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment